Related Experiment Video
Updated: Jan 27, 2026

A 3D Spheroid Model for Glioblastoma
Published on: April 9, 2020
Carbonic Anhydrase XII Inhibitors Overcome Temozolomide Resistance in Glioblastoma
Prashant Mujumdar1, Joanna Kopecka2, Silvia Bua3
1Griffith Institute for Drug Discovery , Griffith University , Don Young Road , Nathan, Brisbane , Queensland 4111 , Australia.
Abstract:
The natural product primary sulfonamide, psammaplin C (1), when used in combination with clinically used chemotherapeutic drugs, including temozolomide, reverses multidrug resistance and increases survival in glioblastoma, a highly aggressive primary brain tumor. We showed previously that the mechanism of action of 1 is novel, acting to indirectly interfere with P-glycoprotein drug efflux activity as a consequence of carbonic anhydrase XII (CA XII) inhibition. To build structure-activity relationships, 45 derivatives of 1 were designed, synthesized, and evaluated against a panel of CA isoforms. Compound 55 was identified as a potent inhibitor of CA XII ( Ki = 0.56 nM) and was investigated in vitro and in vivo using samples from glioblastoma patients. The results strengthen the possibility that co-therapy of temozolomide with a CA XII inhibitor may more effectively treat glioblastoma by suppressing an important temozolomide resistance mechanism.
More Related Videos
Related Concept Videos
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
The Carbon Cycle
Carbon Skeletons
Bioavailability Enhancement: Determination and Conceptual Approaches in Overcoming Bioavailability Problems
Resistivity
Resistance

